Amicus Therapeutics, Inc.
FOLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $528,295 | $399,356 | $329,233 | $305,514 |
| % Growth | 32.3% | 21.3% | 7.8% | – |
| Cost of Goods Sold | $52,943 | $37,326 | $38,599 | $34,466 |
| Gross Profit | $475,352 | $362,030 | $290,634 | $271,048 |
| % Margin | 90% | 90.7% | 88.3% | 88.7% |
| R&D Expenses | $109,362 | $152,381 | $276,677 | $272,049 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $323,379 | $275,270 | $213,041 | $192,710 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $17,735 | $11,590 | $13,036 | $12,723 |
| Operating Expenses | $450,476 | $439,241 | $502,754 | $477,482 |
| Operating Income | $24,876 | -$77,211 | -$212,120 | -$206,434 |
| % Margin | 4.7% | -19.3% | -64.4% | -67.6% |
| Other Income/Exp. Net | -$53,632 | -$72,890 | -$29,919 | -$35,120 |
| Pre-Tax Income | -$28,756 | -$150,101 | -$242,039 | -$241,554 |
| Tax Expense | $27,350 | $1,483 | -$5,471 | $8,906 |
| Net Income | -$56,106 | -$151,584 | -$236,568 | -$250,460 |
| % Margin | -10.6% | -38% | -71.9% | -82% |
| EPS | -0.18 | -0.51 | -0.82 | -0.92 |
| % Growth | 64.7% | 37.8% | 10.9% | – |
| EPS Diluted | -0.18 | -0.51 | -0.82 | -0.92 |
| Weighted Avg Shares Out | 304,381 | 295,165 | 289,057 | 271,422 |
| Weighted Avg Shares Out Dil | 304,381 | 295,165 | 289,057 | 271,422 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,407 | $7,078 | $3,024 | $509 |
| Interest Expense | $49,598 | $50,149 | $37,119 | $32,471 |
| Depreciation & Amortization | $8,547 | $7,873 | $5,342 | $6,209 |
| EBITDA | $29,389 | -$92,079 | -$199,578 | -$202,874 |
| % Margin | 5.6% | -23.1% | -60.6% | -66.4% |